Research

New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors




We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.


This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.


The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.



Latest In Research

02/14
2017

Trial for Patients Doing Well on Nivolumab Expands to UCLA

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squa…

01/27
2017

Stand Up To Cancer Ushers In New Approach to Research with Calls by AACR for SU2C Dream Teams on “Interception” of Pancreas and Lung Cancers, Each Funded at $7 Million

Stand Up To Cancer (SU2C) broke new ground today when the American Association for Cancer Research (AACR), its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception…

01/27
2017

Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising

Patients with advanced non-small cell lung cancer (NSCLC) who receive treatment live longer than those who remain untreated, but the proportion of NSCLC patients with advanced disease who don’t receive treatment has been rising in the Unit…

01/24
2017

Multimillion Dollar Grant Awarded from the National Cancer Institute for Translational Research at UCLA and in TRIO-US

The December, 2016 issue of  THORACIC ONCOLOGY TRANSLATIONAL RESEARCH AT UCLA & TRIO-US announces that the National Cancer Institute has awarded funding to study determinants of benefit from PD-1 inhibitors in patients at UCLA (includ…

01/10
2017

Personalized Medicine Impacting Study Conduct

“We are moving to an era where we use molecular analysis of patient samples either to enroll people in trials or understand how drugs work or don’t work,” said Ross Levine, M.D., a physician-scientist at the Memorial Slo…

12/20
2016

Immunotherapy Agent Improved Quality of Life in Lung Cancer Study

  There was a quality of life improvement for patients with non-small cell lung cancer who were treated with Keytruda compared to those who had standard chemotherapy, according to new data from the trial presented at the IASLC 17th Wo…

12/20
2016

Boehringer Ingelheim HCP Survey: Nearly 20% Of Newly Diagnosed Lung Cancer Patients Tested For EGFR Mutations At Risk Of Missing Out On Personalised Treatments For Their Disease

Recent international survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy. Nearly one in five patients are at r…

12/15
2016

Living Under a Cloud: Examining Air Pollution’s Effects on Lung Cancer

"One takeaway that I find interesting is that there’s been an emphasis on advance screening to detect early-stage lung cancer, so I think that we’re going to be seeing more of it. These are the people who we found air pollution ha…

12/9
2016

ARIAD’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study

New from the World Conference on Lung Cancer: Positive clinical trial results for ALK+ NSCLC patients who had been treated with and experienced disease progression on their most recent crizotinib therapy. Read the article: http://www.bus…

12/9
2016

AstraZeneca pill slashes lung cancer progression in study

AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial. The medicine is designed to help cancer patients with EGFR mutations that are very common in C…



Read More